Mr. Rudy Emmelot reports

PHARMAFORM ANNOUNCES COMMERCIAL MANUFACTURING CONTRACT FOR CORCEPT'S KORLYM

Akela Pharma Inc.'s PharmaForm has been chosen by Corcept Therapeutics Inc. as its primary commercial manufacturer for its newly approved drug product, Korlym. The U.S. Food and Drug Administration approved Corcept's Korlym on Feb. 17, 2012, for patients with endogenous Cushing's syndrome.

PharmaForm, a full-service contract provider of development and manufacturing for the pharmaceutical and biotech industry, has worked with Corcept for several years as a contract provider for services in the development, optimization and validation of the manufacturing process for Corcept's Korlym.

We seek Safe Harbor.